| Business Summary | | Aksys,
Ltd.
provides
hemodialysis
products
and
services
for
patients
suffering
from
end-stage
renal
disease
(ESRD),
known
as
chronic
kidney
failure.
The
Company
has
developed
an
automated
personal
hemodialysis
system,
known
as
the
Aksys
PHD
Personal
Hemodialysis
System
(the
PHD
System),
which
is
designed
to
enable
patients
to
perform
frequent
hemodialysis
at
alternate
sites,
such
as
the
patient's
home,
and
to
thereby
improve
clinical
outcomes,
reduce
total
ESRD
treatment
costs
and
enhance
the
patients'
quality
of
life.
All
of
these
characteristics
have
been
associated
with
frequent
hemodialysis.
The
Company
is
working
toward
satisfying
the
regulatory
requirements
for
Food
and
Drug
Administration
clearance
to
market
the
PHD
System
in
the
United
States.
The
Company
completed
a
clinical
evaluation
of
the
PHD
System
in
November
2000.
In
January
2001,
Aksys
submitted
a
510(k)
pre-market
notification
for
clearance
to
market
the
PHD
System. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Aksys,
Ltd.
is
a
development
stage
company
working
to
provide
hemodialysis
products
and
services
for
patients
suffering
from
end
stage
renal
disease
(ESRD),
commonly
known
as
chronic
kidney
failure.
For
the
six
months
ended
6/30/01,
revenues
totaled
$0,
down
from
$2
million.
Net
loss
rose
24%
to
$9.1
million.
Revenues
reflect
the
absence
of
a
$2
million
joint
development
income.
Higher
loss
was
partially
offset
by
lower
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Egen, 62 Chairman | -- | William Dow, 54 Pres,
CEO, Director | $461K | Dennis Erwin Sr. VP, CFO | -- | Richard Goldhaber Sr.
VP, CTO | 287K | David Bellitt Sr.
VP of Sales and Marketing | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|